Listed by the USPTO as PALENIK, JEFFREY T
Tech Center 3700 • Art Units: 1614 1615 1616 3785
This examiner grants 54% of resolved cases
Jeffrey T. Palenik is assigned to Tech Center 3700 and art unit 1614. His record covers 892 resolved cases, with a 53.5% allowance rate and a median of 1239 days to allowance. The data indicates a substantial docket with an allowance outcome that calls for careful claim strategy and a prosecution plan extending over time.
Interviews are associated with a 27.0% lift in allowance outcomes. The leading companies are L'Oréal, Novaliq GmbH, and Nutrition21, LLC. The leading firms are BIRCH STEWART KOLASCH & BIRCH, LLP, FOLEY HOAG, LLP (General), and HOXIE & ASSOCIATES LLC. Practitioners may combine technical record development, deliberate amendments, and prepared interviews to address examination obstacles.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18484074 | HAIR CARE COMPOSITIONS COMPRISING MALODOR REDUCTION MATERIALS | Non-Final OA | The Procter & Gamble Company |
| 18767430 | ANTIMICROBIAL OR WOUND CARE MATERIALS, DEVICES AND USES | Final Rejection | Smith & Nephew PLC |
| 17997414 | THREE-DIMENSIONALLY PRINTABLE ANTIVIRAL FILAMENT | Non-Final OA | Stratasys, Inc, |
| 18870573 | ANTIVIRAL COMPOSITION AND MEMBER HAVING SAME ON SURFACE | Final Rejection | Shin-Etsu Chemical Co., Ltd. |
| 18849399 | METHODS OF PREPARING CARRIER-BASED DRY POWDERS FOR INHALATION | Non-Final OA | Board of Regents, The University of Texas System |
| 17755832 | ORALLY DISINTEGRATING TABLET | Non-Final OA | Otsuka Pharmaceutical Co., Ltd. |
| 18756678 | COACERVATE CLEANSING COMPOSITION WITH ACNE TREATMENT ACTIVE | Non-Final OA | L'OREAL |
| 18543597 | COMPOSITIONS CONTAINING BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE AND ACTIVE AGENT | Final Rejection | L'OREAL |
| 18265749 | USE OF PARTICULAR AMINO ACIDS AS A PRETREATMENT FOR A PROCESS FOR DYEING OR BLEACHING KERATIN FIBRES | Non-Final OA | L'Oreal |
| 18999125 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | Non-Final OA | Vertex Pharmaceuticals Incorporated |
| 18250121 | COPOLYMER CONTAINING POLY(ETHYLENE GLYCOL) AND POLY(L-AMINO ACID DERIVATIVE), MICROPARTICLES THEREOF AND USE THEREOF IN PHARMACEUTICAL COMPOSITION | Non-Final OA | University of Tsukuba |
| 18550874 | SUTURES | Final Rejection | The Queen's University of Belfast |
| 18718702 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Non-Final OA | GIVAUDAN SA |
| 18859689 | R-KETAMINE LIQUID PREPARATION AND USE THEREOF | Non-Final OA | YICHANG HUMANWELL PHARMACEUTICAL CO., LTD. |
| 18863662 | PRODUCTS AND METHODS FOR THE TREATMENT OF A SKIN CONDITION | Non-Final OA | Individual inventor |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy53.5% of resolved applications examined by Jeffrey T Palenik were allowed (892 resolved cases), compared with 47.9% across Art Unit 1614 over the last five years.
This examiner's interview lift is +27.0 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Jeffrey T Palenik took 1,239 days on average from filing to allowance.
Jeffrey T Palenik examines applications in Art Unit 1614 in Tech Center 3700 (Medical Devices & Mechanical Engineering).
